Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Follicle Stimulating Hormone Market Heading Into 2029?

There has been a consistent increase in the market size of follicle stimulating hormone in the past few years. It is projected to escalate from $2.03 billion in 2024, to $2.12 billion by 2025, growing at a compound annual growth rate (CAGR) of 4.4%. The growth noted in the historic period has been due to factors such as a rise in hormonal disorder incidences, an expanded need for fertility treatments, increased FSH indications, the introduction of new FSH products into the market, and a surge in demand for secure and effective contraceptive alternatives.

In the coming years, the market for follicle stimulating hormone is predicted to experience substantial growth, reaching $2.59 billion by 2029 with a compound annual increase of 5.2%. This projected growth within the given forecast period can be traced back to a variety of factors including the expanding therapeutic applications, increasing need for combination therapy, and a rising demand for effective contraceptive solutions. Additionally, the aging population’s healthcare requirements and market expansion in key areas also contribute to the growth. Key trends emerging in the forecast period are evolved biosimilar FSH products, approval from regulatory authorities and gaining market access, advancements in the production and distribution of FSH technology, and an escalating necessity for effective contraceptive solutions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12486&type=smp

Which Factors Are Pushing The Follicle Stimulating Hormone Market Forward?

The follicle-stimulating hormone market is poised for growth, spurred by the escalating instances of infertility. This condition, which involves an inability in the male or female reproductive system to conceive after 12 months or more of regular unprotected sexual activity, is on the rise. The follicle-stimulating hormone plays a key role in egg development in ovaries and the regulation of menstrual cycles in women, and it fosters testicular growth and the production of a significant protein for male fertility by encouraging the growth of healthy sperm cells. The World Health Organization, a specialized agency of the United Nations based in Switzerland, reported in April 2023 that 1 in 6 adults globally, or approximately 17.5% of the adult population, were impacted by infertility. In October 2023, the Australian Bureau of Statistics, an independent statutory organization in Australia tasked with gathering and analyzing information with the obligation to make evidence-based recommendations to the national, state, and territory governments, stated that recorded births in 2022 were 300,684, marking a 3% decline from 2021. The fertility rate for all Australian women was reported to be 1.63 births per woman. Consequently, this heightened incidence of infertility is fueling the rise of the follicle-stimulating hormone market.

The follicle stimulating hormone market covered in this report is segmented –

1) By Type: Recombinant FSH, Urinary FSH

2) By Application: Infertility Treatment, Assisted Reproductive Technology (ART), Other Applications

3) By End-Users: Infertility Center, Hospitals, Other End-Users

Subsegments:

1) By Recombinant FSH: Pure Recombinant FSH, Mixed Recombinant FSH Formulations

2) By Urinary FSH: Purified Urinary FSH, Urinary FSH Combined With Other Hormones

What Trends Are Currently Influencing Growth In The Follicle Stimulating Hormone Market?

One prominent trend in the follicle-stimulating hormone market is the emphasis on product innovations. Key players in this market are increasingly focusing on the development of novel products to solidify their market position. For example, in July 2024, Proov, an American company specializing in women’s health, introduced the Proov Empower Perimenopause Testing System to the market. The Proov Empower system offers a comprehensive and personalized view on how a woman’s fluctuating hormones impact her overall well-being. This nonintrusive, multi-time point urine test assesses four essential hormones – FSH, E1G as the estrogen marker, PdG as the progesterone marker, and LH, all that play a role in shaping the symptoms and experience of perimenopause. By enabling regular retesting, Proov Empower assists women in monitoring hormone variances and related symptoms, providing a meaningful guide during their transition to menopause.

Which Organizations Are Driving Progress In The Follicle Stimulating Hormone Industry?

Major companies operating in the follicle stimulating hormone market include Pfizer Inc., Novartis AG, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Livzon Pharmaceutical Group Inc., Emcure Pharmaceuticals Ltd., LG Chem’s life sciences, IBSA Group, Bharat Serums and Vaccines Limited, Anhui Anke Biotechnology Group Co. Ltd., Taj Pharmaceuticals Ltd., Genpharm Inc., Cadwell Laboratories Inc., Creative BioMart, Lee Biosolutions Inc., Trumac Healthcare, Midas Pharma GmbH, Biogenix Inc. Pvt. Ltd., Shanghai Techwell Biopharmaceutical Co. Ltd.

https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Follicle Stimulating Hormone Industry?

North America was the largest region in the follicle stimulating hormone market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the follicle stimulating hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12486&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model